4. Regidor PA. Clinical relevance in present day hormonal contraception. Horm Mol Biol Clin Investig.2018;37(1):/j/hmbci.2019.37.issue-1/hmbci-2018-0030/hmbci-2018-0030.xml. Published 2018 Oct 26. doi:10.1515/hmbci-2018-0030.
5. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013;22(4):378–384. doi:10.1089/jwh.2012.3633.
6. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8(47):83334-83342. Published 2017 Aug 3. doi:10.18632/oncotarget.19833.
7. Управление менструальным циклом: новые возможности. Инновации в контрацепции – гибкий пролонгированный режим и цифровые технологии дозирования: информационный бюллетень / М. Б. Хамошина, М. Г. Лебедева, Н. Л. Артикова, Т. А. Добрецова; под ред. В. Е. Радзинского – М.: Редакция журнала StatusPraesens, 2016. – 24 с.
8. Сперофф Леон, Дарни Филип Д. Клиническое руководство по контрацепции / Под ред. В.Н. Прилепской. Бином, 2009.
9. Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014;:CD004695. doi:10.1002/14651858.CD004695.pub3.
10. Nash Zachary, Thwaites Annette, Davies Melanie. Tailored regimens for combined hormonal contraceptives BMJ 2020; 368:m200.
11. FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2019).
12. Gloviczki P. Handbook of Venous Disorders Guidelines of the American Venous Forum. 3rd ed. / ed. Gloviczki P. Hodder Arnold Publishers, 2009. P. 624.
13. Клинические рекомендации РООМ по профилактике РМЖ, дифференциальной диагностике, лечению, предопухолевых и доброкачественных заболеваний молочных желёз / И. В. Высоцкая, В. П. Летягин, В. Г. Черенков и др. М., 2015. 21 с.
14. Vogt C, Schaefer M. Disparities in knowledge and interest about benefits and risks of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2011;16(3):183–193. doi:10.3109/13625187.2011.561938.
15. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD003987. DOI: 10.1002/14651858.CD003987.pub5.
16. Nelson AL. Combined oral contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, et al.editor(s). Contraceptive Technology. 19th Edition. New York: Ardent Media, Inc., 2007:193–270.
17. Ingela Lindh, Agneta Andersson Ellström, Ian Milsom. The long-term influence of combined oral contraceptives on body weight, Human Reproduction, 2011, pp. 1917–1924, 26/7, DOI: 10.1093/humrep/der094.
18. The European Agency for the Evaluation of Medicinal Products Post-authorisation Evaluation of Medicines for Human use London, 28 September 2001 Doc.
19. Dinger J.C., et al. The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation // Contraception 2007; 75 (5): 344-54.
20. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Product information updated to help women make informed decisions about their choice of contraception // European Medicines Agency. – 2014. – 4 р.
21. Heit J., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study //Ann. Intern. Med. – 2005. – Vol. 143 (10). – Р. 697–706.
22. Carrie Armstrong ACOG Guidelines on Noncontraceptive Uses of Hormonal Contraceptives // Am. Fam. Physician. 2010. Aug 1. Vol. 82 (3). P. 288–295.
23. Curtis K.M., Tepper N.K., Jatlaoui T.C. et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. // MMWR Recomm. Rep. 2016. Vol. 65 (3). P.1. [Epub 2016 Jul 29] [PMID 27467196].
24. Calhoun A.H. Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk? // Headache. 2017. Vol. 57 (2). P. 184. [Epub 2016 Oct 24] [PMID 27774589].
25. Chürks M. et al. Migraine and cardiovascular disease: systematic review and meta-analysis // BMJ. 2009. Vol. 339. P. 657–665. [PMID: 19861375].
26. Tepper N.K., Whiteman M.K., Zapata L.B. et al. Safety of hormonal contraceptives among women with migraine: A systematic review. //Contraception. 2016. Vol. 94 (6). P. 630–640. [PMID 27153744].
27. Edlow A.G., Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. // Rev. Obstet. Gynecol. 2010. Vol. 3 (2). P. 55–65. [PMID: 20842283].
28. Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review./Eur J Contracept Reprod Health Care. 2016;21(5):347. Epub 2016 Aug 15.
29. Wiréhn AB, Foldemo A, Josefsson A et al. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study./ Eur J Contracept Reprod Health Care. 2010;15(1):41.
30. Skovlund CW, Mørch LS, Kessing LV, LidegaardØ. Association of Hormonal Contraception With Depression./ JAMA Psychiatry. 2016;73(11):1154.
31. Harlow BL, Wise LA, Otto MW et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles./ Arch Gen Psychiatry. 2003 Jan;60(1):29–36.
32. Joffe H, Cohen LS, Harlow BL Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration./ Am J Obstet Gynecol. 2003 Dec;189(6):1523-30.
33. Toffol E, Heikinheimo O, Koponen P et al. Hormonal contraception and mental health: results of a population-based study./ Hum Reprod. 2011 Nov;26(11):3085-93. Epub 2011 Aug 12.
34. Keyes KM, Cheslack-Postava K, Westhoff C et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States./ Am J Epidemiol. 2013 Nov;178(9):1378-88. Epub 2013 Sep 15.
35. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression./ JAMA Psychiatry. 2016; 73(11):1154.
36. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Suicide Attempts and Suicides./ Am J Psychiatry. 2018 Apr 1;175(4):336–342. Epub 2017 Nov 17.
37. Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception./N Engl J Med. 2012 Jun 14;366(24):2257-66.
38. Berlin I, Aubin HJ, Thomas D. Comment on the Association of Hormonal Contraception With Suicide Attempts and Suicides./ Am J Psychiatry. 2018 Jul 1;175(7):683.
39. Heinemann L. A., Thiel C., Assmann A., Möhner S. Frequency and reasons for switching/stopping use of oral contraceptives. Results of the German Cohort Study on Women Health // Zentralbl. Gynakol. 2001. Vol. 123. N 10. P. 568–577.
40. Burrows L.J., Basha M., Goldstein A.T.The effects of hormonal contraceptives on female sexuality: a review. J Sex Med 2012 Sep 12;9 (9):2213–23. Epub 2012 Jul 12.
41. Boozalis A, Tutlam NT, Chrisman Robbins C. Sexual Desire and Hormonal Contraception // Obstet Gynecol. 2016 Mar;127 (3): 563-72.
42. Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review./ Eur J Contracept Reprod Health Care. 2013 Feb;18 (1):27–43.
43. Zethraeus N, Dreber A, Ranehill E. Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial.// J Clin Endocrinol Metab. 2016 Nov;101(11):4046–4053. Epub 2016 Aug 15.
44. Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.// J Med Assoc Thai. 2006;89 Suppl 4:S17.
45. Bancroft J, Davidson DW, Warner P. Androgens and sexual behaviour in women using oral contraceptives.// Clin Endocrinol (Oxf). 1980;12(4):327.
46. Di Carlo С., Gargano V., De Rosa N., Antonio Tommaselli G. A. et al. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age // Gynecol. Endocrinol. 2014. Vol. 30. N 12. P. 925–928.
47. Goldstein I.et al.Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review / Mayo Clinic Proceedings, Volume 92, Issue 1, 114–128.
48. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users oral contraceptives: cohort data from the Royal College of General Practitioners oral contraception study. BMJ 2007; 335: 651.
49. Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers [published online January 18, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4942.
50. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiology, Biomarkers & Prevention 2013; 22(11):1931–1943.
51. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncology 2015; 16(9):1061–1070.
52. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.// J Reprod Med. 1996; 41(5 Suppl):428.
53. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.// J Reprod Med. 1996; 41(5 Suppl):419.